Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.
Carmen Joseph Allegra
Consultant or Advisory Role - Sanofi ; Sanofi
Radek Lakomy
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Regeneron; Regeneron; Roche; Roche; Sanofi ; Sanofi
Jana Prausová
No relevant relationships to disclose
Paul Ruff
Honoraria - Amgen; Merck KGaA; Pfizer; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Pfizer; Sanofi
Other Remuneration - Amgen; Pfizer; Roche
Guy Van Hazel
No relevant relationships to disclose
Vladimir Mikhailovich Moiseyenko
No relevant relationships to disclose
David R Ferry
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Joseph J McKendrick
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Sanofi ; Sanofi